Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
Queensland Health
Daiichi Sankyo
Teva
McKinsey
Healthtrust
UBS
AstraZeneca
Fish and Richardson

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,126,941

« Back to Dashboard

Which drugs does patent 9,126,941 protect, and when does it expire?


Patent 9,126,941 protects XTANDI and is included in one NDA. There has been one Paragraph IV challenge on Xtandi.

This patent has ninety-seven patent family members in twenty-five countries.

Summary for Patent: 9,126,941

Title:Treatment of hyperproliferative disorders with diarylhydantoin compounds
Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s): Sawyers; Charles L. (New York, NY), Jung; Michael E. (Los Angeles, CA), Chen; Charlie D. (Los Angeles, CA), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (Nanuet, NY)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:13/448,964
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AstellasXTANDIenzalutamideCAPSULE;ORAL203415-001Aug 31, 2012RXYesYes► Subscribe► Subscribe► SubscribeTHE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,126,941

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,709,517Diarylhydantoin compounds► Subscribe
8,648,105Diarylthiohydantoin compounds► Subscribe
8,183,274Treatment of hyperproliferative disorders with diarylhydantoin compounds► Subscribe
8,110,594Diarylthiohydantoin compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,126,941

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus1116426► Subscribe
Denmark1893196► Subscribe
Denmark2444085► Subscribe
European Patent Office1893196► SubscribeC300632Netherlands► Subscribe
European Patent Office1893196► SubscribeCA 2013 00065Denmark► Subscribe
European Patent Office1893196► SubscribePA2013029Lithuania► Subscribe
European Patent Office1893196► Subscribe1390060-0Sweden► Subscribe
European Patent Office1893196► SubscribeC20130036 00106Estonia► Subscribe
European Patent Office1893196► Subscribe169 50005-2013Slovakia► Subscribe
European Patent Office1893196► Subscribe92338Luxembourg► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
UBS
Queensland Health
McKinsey
Dow
Cantor Fitzgerald
Covington
Teva
Medtronic
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot